247 related articles for article (PubMed ID: 23199508)
21. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
22. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
23. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
24. Is the conquest of Hepatitis C imminent?
Rivett L; Alexander G
Expert Rev Mol Med; 2019 Mar; 21():e3. PubMed ID: 30909984
[TBL] [Abstract][Full Text] [Related]
25. Approaches to the development of novel inhibitors of hepatitis C virus replication.
Clarke BE
J Viral Hepat; 1995; 2(1):1-8. PubMed ID: 7493290
[TBL] [Abstract][Full Text] [Related]
26. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
27. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
28. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.
Georgel P; Schuster C; Zeisel MB; Stoll-Keller F; Berg T; Bahram S; Baumert TF
Trends Mol Med; 2010 Jun; 16(6):277-86. PubMed ID: 20537953
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
30. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
[TBL] [Abstract][Full Text] [Related]
31. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
Pietschmann T
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807238
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
33. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
34. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
Maggi F; Focosi D; Pistello M
Curr Drug Targets; 2017; 18(7):811-825. PubMed ID: 26245474
[TBL] [Abstract][Full Text] [Related]
35. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
Hartlage AS; Walker CM; Kapoor A
J Virol; 2020 May; 94(10):. PubMed ID: 32102885
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
37. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets.
Alazard-Dany N; Denolly S; Boson B; Cosset FL
Viruses; 2019 Jan; 11(1):. PubMed ID: 30621318
[TBL] [Abstract][Full Text] [Related]
38. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.
Chamoun-Emanuelli AM; Pécheur EI; Chen Z
Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406
[TBL] [Abstract][Full Text] [Related]
39. Cyclophilin inhibitors.
Gallay PA
Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
[TBL] [Abstract][Full Text] [Related]
40. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.
Shin EC; Han JW; Kang W; Kato T; Kim SJ; Zhong J; Kim S; Park SH; Sung PS; Watashi K; Park JY; Windisch MP; Oh JW; Wakita T; Han KH; Jang SK
Viruses; 2020 Mar; 12(3):. PubMed ID: 32168867
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
